An "all-in-one" silver nanoprism platform for targeted tumor theranostics.
Xuemei Zeng,Shuangqian Yan,Chao Di,Mengcheng Lei,Peng Chen,Wei Du,Yang Jin,Bi-Feng Liu
DOI: https://doi.org/10.1021/acsami.9b21166
IF: 9.5
2020-01-01
ACS Applied Materials & Interfaces
Abstract:Design multifunctional theranostic nanoplatform with optional therapeutic strategies is highly desirable to select the most suitable therapeutic manners for the patient's cancer treatment. Among all shapes of silver materials, silver nanoprism was reported to have great potential in photothermal therapy owing to its strong surface plasmon resonance (SPR) band in near-infrared region. But its instability in physicochemical environments as well as its severe toxicity confined its further application. To overcome this, herein, we demonstrated a silver prism-polydopamine hybrid nanoplatform for tumor treatments with three therapeutic strategies. Specifically, the polydopamine coating makes silver prism with excellent stability, high photothermal conversion, long term in vivo biocompatibility, and easy to decorate targeting ligand as well as drug delivery. Upon near-infrared laser irradiation (808 nm, 1 W/cm2), tumors can be eradicated by the as-prepared nanoparticle through monomodal photothermal therapy (PTT). Besides, when combined with chemical drug, this nanoparticle is able to inhibit tumor growth via combined photochemotherapy under a lower laser treatment (0.7 W/cm2). Furthermore, by supplementing with immune checkpoint blockade, the realized synergistic photochemoimmunotherapy exhibits high efficacy to inhibit tumor relapse and metastasis. Moreover, owing to the high photothermal conversion efficiency, great X-ray attenuation ability of silver nanoprism, our designed nanoplatform can be used to photoacoustic (PA), computed tomography (CT), and infrared thermal (IRT) multimodal imaging. Our study provides a multifunctional nanoparticle for tumor theranostic, and this therapeutic strategies-optional nanoplatform shows promise in the future biomedicine.